R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Accounts Receivables
ÂĄ238.3m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Accounts Receivables
ÂĄ8.8B
CAGR 3-Years
19%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Accounts Receivables
ÂĄ2.6B
CAGR 3-Years
25%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Accounts Receivables
ÂĄ6.1B
CAGR 3-Years
28%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Accounts Receivables
ÂĄ4.1B
CAGR 3-Years
32%
CAGR 5-Years
31%
CAGR 10-Years
33%
W
WuXi XDC Cayman Inc
HKEX:2268
Accounts Receivables
ÂĄ853.3m
CAGR 3-Years
225%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Accounts Receivables?
Accounts Receivables
238.3m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Accounts Receivables amounts to 238.3m CNY.

What is R&G PharmaStudies Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
23%

Over the last year, the Accounts Receivables growth was 8%. The average annual Accounts Receivables growth rates for R&G PharmaStudies Co Ltd have been 23% over the past three years .

Back to Top